David A. Siegel Y M Abs Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 97,700 shares of YMAB stock, worth $1.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

97,700

Previous 130,400 25.08%

Holding current value

$1.27 Million

Previous $2.12 Million 44.34%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$11.6 - $17.25 $379,320 - $564,075	-32,700 Reduced 25.08%	97,700 $1.18 Million
Q1 2024 May 15, 2024	SELL	$6.57 - $18.69 $227,322 - $646,674	-34,600 Reduced 20.97%	130,400 $2.12 Million
Q4 2023 Feb 14, 2024	SELL	$4.88 - $7.42 $181,536 - $276,024	-37,200 Reduced 18.4%	165,000 $1.13 Million
Q3 2023 Nov 14, 2023	SELL	$4.86 - $7.23 $38,880 - $57,840	-8,000 Reduced 3.81%	202,200 $1.1 Million
Q2 2023 Aug 14, 2023	BUY	$5.68 - $10.34 $5,680 - $10,340	1,000 Added 0.48%	210,200 $1.43 Million
Q1 2023 May 15, 2023	BUY	$2.83 - $5.11 $404,973 - $731,241	143,100 Added 216.49%	209,200 $1.05 Million
Q4 2022 Feb 14, 2023	BUY	$3.0 - $15.17 $198,300 - $1 Million	66,100 New	66,100 $322,000
Q2 2022 Aug 15, 2022	SELL	$8.22 - $15.13 $91,242 - $167,943	-11,100 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$6.55 - $17.42 $87,115 - $231,686	-13,300 Reduced 54.51%	11,100 $132,000
Q4 2021 Feb 14, 2022	SELL	$15.51 - $29.31 $381,546 - $721,026	-24,600 Reduced 50.2%	24,400 $396,000
Q3 2021 Nov 15, 2021	SELL	$27.47 - $37.31 $2.37 Million - $3.22 Million	-86,300 Reduced 63.78%	49,000 $1.4 Million
Q2 2021 Aug 16, 2021	SELL	$25.45 - $37.64 $2.67 Million - $3.94 Million	-104,800 Reduced 43.65%	135,300 $4.57 Million
Q1 2021 May 17, 2021	BUY	$29.16 - $51.96 $3.7 Million - $6.59 Million	126,900 Added 112.1%	240,100 $7.26 Million
Q4 2020 Feb 16, 2021	BUY	$37.86 - $54.26 $465,678 - $667,398	12,300 Added 12.19%	113,200 $5.61 Million
Q3 2020 Nov 16, 2020	BUY	$35.13 - $43.62 $758,808 - $942,192	21,600 Added 27.24%	100,900 $3.87 Million
Q2 2020 Aug 14, 2020	BUY	$23.66 - $49.53 $352,534 - $737,997	14,900 Added 23.14%	79,300 $3.43 Million
Q1 2020 May 15, 2020	BUY	$14.39 - $35.8 $303,629 - $755,379	21,100 Added 48.73%	64,400 $1.68 Million
Q4 2019 Feb 14, 2020	BUY	$23.81 - $33.78 $1.03 Million - $1.46 Million	43,300 New	43,300 $1.35 Million

Others Institutions Holding YMAB

# of Institutions

Shares Held

23.8M

Call Options Held

19.4K

Put Options Held

300

View Full List

About Y-mAbs Therapeutics, Inc.

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $566M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

More about YMAB

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account